Fed. Circ. Looks At Early Statements In Neulasta Patent Row
By Matthew Bultman (October 3, 2017, 7:56 PM EDT) -- Federal Circuit judges on Tuesday questioned how much weight courts should put on statements made in the prelitigation process by companies making copycat versions of biologic drugs, as Amgen looks to overturn a ruling that cleared Apotex of infringing a patent related to its blockbuster biologic Neulasta.
The 40-minute argument at the Benjamin Cardozo School of Law in Manhattan came in an appeal that was filed after a Florida federal judge last year ruled Apotex's Neulasta and Neupogen biosimilars did not infringe Amgen's patent.
Much of the argument focused on what to do with statements that Apotex made in pre-litigation letters...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!